We concluded that the simultaneous inhibition of PARP and Akt using olaparib and capivasertib triggers metabolic collapse and apoptotic cell death in breast cancer cells, particularly in triple-negative breast cancer (TNBC) and MCF7 cells. This evidence concerns the gene PARP1 and triple-negative breast carcinoma.